2seventy Bio (NASDAQ: TSVT) Discontinues Enrollment in Key Blood Cancer Therapy Trial
2seventy Bio (NASDAQ: TSVT) will discontinue enrolling patients in a late-stage study of its cell therapy Abecma, developed in partnership […]
2seventy Bio (NASDAQ: TSVT) Discontinues Enrollment in Key Blood Cancer Therapy Trial Read More »
